BioVaxys Technology Corp.
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer.
BioVaxys Technology Corp. (BIOV)
BioVaxys Technology Corp. (BIOV)
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| CIBC World Markets Inc. | 50,000 | 0.035 | 0.04 | 61,000 | Anonymous |
| TD Securities Inc. | 1,000 | 0.035 | 0.045 | 90,000 | CIBC World Markets Inc. |
| Questrade Inc. | 50,000 | 0.035 | 0.045 | 20,000 | Scotia Capital Inc. |
| Questrade Inc. | 11,000 | 0.035 | 0.045 | 40,000 | TD Securities Inc. |
| CIBC World Markets Inc. | 100,000 | 0.035 | 0.045 | 40,000 | TD Securities Inc. |
| TD Securities Inc. | 100,000 | 0.035 | 0.045 | 20,000 | Questrade Inc. |
| TD Securities Inc. | 20,000 | 0.035 | 0.045 | 1,000 | National Bank Financial Inc. |
| Anonymous | 1,000 | 0.035 | 0.045 | 1,000 | National Bank Financial Inc. |
| TD Securities Inc. | 5,000 | 0.035 | 0.045 | 1,000 | National Bank Financial Inc. |
| RBC Capital Markets | 25,000 | 0.035 | 0.045 | 1,000 | National Bank Financial Inc. |
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| Instinet Canada Limited | 20,000 | 0.035 | 0.00 | 0 | |
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 20 | 453,000 | 0.035 | 0.04 | 61,000 | 1 |
| 11 | 191,000 | 0.03 | 0.045 | 277,000 | 11 |
| 5 | 241,000 | 0.025 | 0.05 | 573,000 | 15 |
| 5 | 141,000 | 0.02 | 0.055 | 215,000 | 7 |
| 2 | 201,000 | 0.015 | 0.06 | 46,000 | 7 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 1 | 20,000 | 0.035 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Date/Time | Price | Change | Volume | Buyer | Seller | Venue |
|---|---|---|---|---|---|---|
| Apr 25, 16:24 | 0.04 | 0.00 | 19,000 | TD Securities Inc. | Anonymous | CSE |
| Apr 25, 16:24 | 0.04 | 0.00 | 14,000 | TD Securities Inc. | Anonymous | CSE |
| Apr 25, 15:37 | 0.04 | 0.00 | 14,000 | CIBC World Markets Inc. | Anonymous | CSE |
| Apr 25, 15:37 | 0.04 | 0.00 | 10,000 | CIBC World Markets Inc. | Anonymous | CSE |
| Apr 25, 15:30 | 0.04 | 0.00 | 10,000 | CIBC World Markets Inc. | Anonymous | CSE |
Company Info
SEDAR Information
Company Info
Capitalization
Company Officers
Bulletins
2024-0715 - Reinstatement - BioVaxys Technology Corp. (BIOV)
le 16 juillet/July 2024
Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.
The Company has rectified the situation that gave rise to the suspension.
____________________________
Avec effet immédiat, BioVaxys Technology Corp. sera réintégrée à la négociation.
La Société a rectifié la situation qui a donné lieu à la suspension.
CSE Filings
